In the Abstract, two typographical errors were identified. In the last sentence of the Patients and Methods section, the original version incorrectly stated: “These 33 patients were stratified into two groups based on the duration of BTKi exposure: ≥x months versus <2 months.” In the first sentence of the Results section, it incorrectly stated: “The R/R DLBCL patients receiving BTKi for ≥o months demonstrated a higher overall response rate than the patients receiving BTKi for <2 month.”.
The corrected Abstract reads: “These 33 patients were stratified into two groups based on the duration of BTKi exposure: ≥2 months versus <2 months,” and “The R/R DLBCL patients receiving BTKi for ≥2 months demonstrated a higher overall response rate than the patients receiving BTKi for <2 months.”
The original version of this article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
bridging therapy, BTK inhibitors, chimeric antigen receptor (CAR), diffuse large B-cell lymphoma, nicotinamide phosphoribosyl transferase, programmed cell death 1
Citation
Wang J, Cui R, Qi Y, Mu J, Li X, Li Q and Deng Q (2026) Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. Front. Immunol. 17:1814535. doi: 10.3389/fimmu.2026.1814535
Received
20 February 2026
Revised
20 February 2026
Accepted
23 February 2026
Published
09 March 2026
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
17 - 2026
Updates
Copyright
© 2026 Wang, Cui, Qi, Mu, Li, Li and Deng.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qi Deng, kachydeng@126.com
†ORCID: Jia Wang, orcid.org/0000-0001-8518-6948; Qi Deng, orcid.org/0000-0002-3646-4953
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.